A new prognostic classification for overall survival in asian patients with previously untreated metastatic renal cell carcinoma

Nobuo Shinohara, Katsuya Nonomura, Takashige Abe, Satoru Maruyama, Takao Kamai, Masayuki Takahashi, Katsunori Tatsugami, Shigeaki Yokoi, Takashi Deguchi, Hiroomi Kanayama, Koji Oba, Seiji Naito

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The aims of the present study were to: (i) develop a clinically useful prognostic classification in Asian patients with metastatic renal cell carcinoma (RCC) by combining metastatic features with several pretreatment parameters; and (ii) evaluate the validity of this prognostic classification. Baseline characteristics and outcomes were collected for 361 patients who underwent interferon-α-based therapy between 1995 and 2005. Relationships between overall survival (OS) and potential prognostic factors were assessed using Cox's proportional hazard model. The predictive performance of the model was evaluated using bootstrap resampling procedures and by using an independent dataset obtained from randomly selected institutions. The predictive accuracy was measured using the concordance index (c-index). Four factors were identified as independent prognostic factors: time from initial diagnosis to treatment, anemia, elevated lactate dehydrogenase (LDH), and poor prognostic metastatic group (liver only, bone only, or multiple organ metastases). Each patient was assigned to one of three risk groups: favorable risk (none or one factor; n = 120), in which median OS was 51 months; intermediate risk (two factors; n = 101), in which median OS was 21 months; and poor risk (three or four factors; n = 102), in which median OS was 10 months. The c-index was 0.72 in the original dataset and 0.72 in 500 random bootstrap samples. In the independent dataset for external validation, the c-index was 0.73. Thus, the new prognostic classification is easily applicable for Asian patients with previously untreated metastatic RCC and should be incorporated into patient care, as well as clinical trials performed in Asia.

Original languageEnglish
Pages (from-to)1695-1700
Number of pages6
JournalCancer Science
Volume103
Issue number9
DOIs
Publication statusPublished - Sep 1 2012

Fingerprint

Renal Cell Carcinoma
Survival
L-Lactate Dehydrogenase
Proportional Hazards Models
Interferons
Anemia
Patient Care
Clinical Trials
Neoplasm Metastasis
Bone and Bones
Liver
Therapeutics
Datasets

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

A new prognostic classification for overall survival in asian patients with previously untreated metastatic renal cell carcinoma. / Shinohara, Nobuo; Nonomura, Katsuya; Abe, Takashige; Maruyama, Satoru; Kamai, Takao; Takahashi, Masayuki; Tatsugami, Katsunori; Yokoi, Shigeaki; Deguchi, Takashi; Kanayama, Hiroomi; Oba, Koji; Naito, Seiji.

In: Cancer Science, Vol. 103, No. 9, 01.09.2012, p. 1695-1700.

Research output: Contribution to journalArticle

Shinohara, N, Nonomura, K, Abe, T, Maruyama, S, Kamai, T, Takahashi, M, Tatsugami, K, Yokoi, S, Deguchi, T, Kanayama, H, Oba, K & Naito, S 2012, 'A new prognostic classification for overall survival in asian patients with previously untreated metastatic renal cell carcinoma', Cancer Science, vol. 103, no. 9, pp. 1695-1700. https://doi.org/10.1111/j.1349-7006.2012.02351.x
Shinohara, Nobuo ; Nonomura, Katsuya ; Abe, Takashige ; Maruyama, Satoru ; Kamai, Takao ; Takahashi, Masayuki ; Tatsugami, Katsunori ; Yokoi, Shigeaki ; Deguchi, Takashi ; Kanayama, Hiroomi ; Oba, Koji ; Naito, Seiji. / A new prognostic classification for overall survival in asian patients with previously untreated metastatic renal cell carcinoma. In: Cancer Science. 2012 ; Vol. 103, No. 9. pp. 1695-1700.
@article{c406bc9f4e2043bfb7848e064466039a,
title = "A new prognostic classification for overall survival in asian patients with previously untreated metastatic renal cell carcinoma",
abstract = "The aims of the present study were to: (i) develop a clinically useful prognostic classification in Asian patients with metastatic renal cell carcinoma (RCC) by combining metastatic features with several pretreatment parameters; and (ii) evaluate the validity of this prognostic classification. Baseline characteristics and outcomes were collected for 361 patients who underwent interferon-α-based therapy between 1995 and 2005. Relationships between overall survival (OS) and potential prognostic factors were assessed using Cox's proportional hazard model. The predictive performance of the model was evaluated using bootstrap resampling procedures and by using an independent dataset obtained from randomly selected institutions. The predictive accuracy was measured using the concordance index (c-index). Four factors were identified as independent prognostic factors: time from initial diagnosis to treatment, anemia, elevated lactate dehydrogenase (LDH), and poor prognostic metastatic group (liver only, bone only, or multiple organ metastases). Each patient was assigned to one of three risk groups: favorable risk (none or one factor; n = 120), in which median OS was 51 months; intermediate risk (two factors; n = 101), in which median OS was 21 months; and poor risk (three or four factors; n = 102), in which median OS was 10 months. The c-index was 0.72 in the original dataset and 0.72 in 500 random bootstrap samples. In the independent dataset for external validation, the c-index was 0.73. Thus, the new prognostic classification is easily applicable for Asian patients with previously untreated metastatic RCC and should be incorporated into patient care, as well as clinical trials performed in Asia.",
author = "Nobuo Shinohara and Katsuya Nonomura and Takashige Abe and Satoru Maruyama and Takao Kamai and Masayuki Takahashi and Katsunori Tatsugami and Shigeaki Yokoi and Takashi Deguchi and Hiroomi Kanayama and Koji Oba and Seiji Naito",
year = "2012",
month = "9",
day = "1",
doi = "10.1111/j.1349-7006.2012.02351.x",
language = "English",
volume = "103",
pages = "1695--1700",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - A new prognostic classification for overall survival in asian patients with previously untreated metastatic renal cell carcinoma

AU - Shinohara, Nobuo

AU - Nonomura, Katsuya

AU - Abe, Takashige

AU - Maruyama, Satoru

AU - Kamai, Takao

AU - Takahashi, Masayuki

AU - Tatsugami, Katsunori

AU - Yokoi, Shigeaki

AU - Deguchi, Takashi

AU - Kanayama, Hiroomi

AU - Oba, Koji

AU - Naito, Seiji

PY - 2012/9/1

Y1 - 2012/9/1

N2 - The aims of the present study were to: (i) develop a clinically useful prognostic classification in Asian patients with metastatic renal cell carcinoma (RCC) by combining metastatic features with several pretreatment parameters; and (ii) evaluate the validity of this prognostic classification. Baseline characteristics and outcomes were collected for 361 patients who underwent interferon-α-based therapy between 1995 and 2005. Relationships between overall survival (OS) and potential prognostic factors were assessed using Cox's proportional hazard model. The predictive performance of the model was evaluated using bootstrap resampling procedures and by using an independent dataset obtained from randomly selected institutions. The predictive accuracy was measured using the concordance index (c-index). Four factors were identified as independent prognostic factors: time from initial diagnosis to treatment, anemia, elevated lactate dehydrogenase (LDH), and poor prognostic metastatic group (liver only, bone only, or multiple organ metastases). Each patient was assigned to one of three risk groups: favorable risk (none or one factor; n = 120), in which median OS was 51 months; intermediate risk (two factors; n = 101), in which median OS was 21 months; and poor risk (three or four factors; n = 102), in which median OS was 10 months. The c-index was 0.72 in the original dataset and 0.72 in 500 random bootstrap samples. In the independent dataset for external validation, the c-index was 0.73. Thus, the new prognostic classification is easily applicable for Asian patients with previously untreated metastatic RCC and should be incorporated into patient care, as well as clinical trials performed in Asia.

AB - The aims of the present study were to: (i) develop a clinically useful prognostic classification in Asian patients with metastatic renal cell carcinoma (RCC) by combining metastatic features with several pretreatment parameters; and (ii) evaluate the validity of this prognostic classification. Baseline characteristics and outcomes were collected for 361 patients who underwent interferon-α-based therapy between 1995 and 2005. Relationships between overall survival (OS) and potential prognostic factors were assessed using Cox's proportional hazard model. The predictive performance of the model was evaluated using bootstrap resampling procedures and by using an independent dataset obtained from randomly selected institutions. The predictive accuracy was measured using the concordance index (c-index). Four factors were identified as independent prognostic factors: time from initial diagnosis to treatment, anemia, elevated lactate dehydrogenase (LDH), and poor prognostic metastatic group (liver only, bone only, or multiple organ metastases). Each patient was assigned to one of three risk groups: favorable risk (none or one factor; n = 120), in which median OS was 51 months; intermediate risk (two factors; n = 101), in which median OS was 21 months; and poor risk (three or four factors; n = 102), in which median OS was 10 months. The c-index was 0.72 in the original dataset and 0.72 in 500 random bootstrap samples. In the independent dataset for external validation, the c-index was 0.73. Thus, the new prognostic classification is easily applicable for Asian patients with previously untreated metastatic RCC and should be incorporated into patient care, as well as clinical trials performed in Asia.

UR - http://www.scopus.com/inward/record.url?scp=84865793303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865793303&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2012.02351.x

DO - 10.1111/j.1349-7006.2012.02351.x

M3 - Article

C2 - 22642767

AN - SCOPUS:84865793303

VL - 103

SP - 1695

EP - 1700

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 9

ER -